Skip to main content
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRVI ISIN · US89532M1018 US Manufacturing
Open in API
Filings indexed 505 across all filing types
Latest filing 2019-05-07 Director's Dealing
Country US United States of America
Listing US TRVI

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com/

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary program is aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent a significant unmet medical need with no approved therapies in the United States. Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting both central and peripheral nerve pathways believed to cause chronic cough. The company has reported positive results from its Phase 2b CORAL trial in IPF chronic cough and its Phase 2a RIVER trial in refractory chronic cough.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2019-05-07 English
FORM 3
Director's Dealing
2019-05-07 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock incentive plans and employee stock purchase plans. It includes details about the plans, registration fee calculations, indemnification provisions, and incorporation by reference of other filings. It is not a financial report like an Annual Report or Interim Report, nor is it an announcement of voting results or a management change. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is a full filing, not just an announcement or certification.
2019-05-07 English
FWP
Capital/Financing Update Classification · 95% confidence The document is titled 'Issuer Free Writing Prospectus' and references a Preliminary Prospectus and Registration Statement on Form S-1. It discusses details of a stock offering, including number of shares offered, pricing, use of proceeds, and beneficial ownership of shares. The content focuses on fundraising activities, share issuance, and private placement concurrent with the offering. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document is clearly related to capital raising and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2019-05-07 English
Regulatory Filings 2019
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, form names, fiscal period dates, or document titles that can be used to identify the filing type. The text is not a typical financial report or announcement and lacks substantive financial data or narrative. Given the absence of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS).
2019-05-07 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the U.S. Securities and Exchange Commission regarding an Amendment No. 2 to a Registration Statement on Form S-1 filed by Trevi Therapeutics, Inc. It is a correspondence responding to SEC staff comments about the registration statement, specifically about disclosure revisions related to a concurrent private placement. The document does not contain financial statements or substantive financial data itself but is a regulatory correspondence related to a registration filing. It is not an annual report, earnings release, or any other financial report type. It is a regulatory filing responding to SEC comments, which fits the category of Regulatory Filings (RNS). The document length is under 5,000 characters and is a letter, not the report itself.
2019-05-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.